Combination of BGJ398 with either a pan-PI3K inhibitor or a specific PIK3CA inhibitor shows synergy in FGFR2 mutant endometrial cancer cell lines

被引：1
|
作者：
Packer, L. [1 ]
Geng, X. [1 ]
Bonazzi, V. [1 ]
Mahon, C. [1 ]
Ju, R. [1 ]
Stephenson, S. [1 ]
Pollock, P. [1 ]
机构：
[1] Queensland Univ Technol, Sch Biomed Sci, Inst Hlth & Innovat, Translat Res Inst, Brisbane, Qld, Australia
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 61卷
关键词：
D O I：
10.1016/S0959-8049(16)61523-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
661
引用
收藏
页码：S148 / S148
页数：1
相关论文
共 50 条
  • [21] GDC-0077 is a selective PI3K alpha inhibitor with robust efficacy in PIK3CA mutant hormone-positive breast cancer models
    Edgar, Kyle
    Hong, Rebecca
    Song, Kyung
    Schmidt, Steven
    Hafner, Marc
    Arrazate, Alfonso
    Williams, Erin
    De La Cruz, Cecile
    Oeh, Jason
    Sampath, Deepak
    Staben, Steve
    Friedman, Lori
    CANCER RESEARCH, 2020, 80 (04)
  • [22] Generation of a novel PIK3CA mutated duodenal cancer mouse model and evaluation of PI3K inhibitor therapeutic effects
    Sugimori, Makoto
    Sugimori, Kazuya
    Kanemaru, Yushi
    Tsuchiya, Hiromi
    Suzuki, Yoshimasa
    Nakamori, Yoshinori
    Onodera, Sho
    Tsuyuki, Sho
    Hirotani, Akane
    Sawada, Atsushi
    Hirasawa, Kingo
    Nozaki, Akito
    Numata, Kazushi
    Kunisaki, Chikara
    Maeda, Shin
    CANCER SCIENCE, 2024, 115 : 1893 - 1893
  • [23] Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting
    Pivonello, Claudia
    Patalano, Roberta
    Solari, Domenico
    Auriemma, Renata S.
    Frio, Federico
    Vitulli, Francesca
    Grasso, Ludovica F. S.
    Di Cera, Marialuisa
    De Martino, Maria Cristina
    Cavallo, Luigi M.
    Cappabianca, Paolo
    Colao, Annamaria
    Pivonello, Rosario
    ENDOCRINE, 2018, 62 (03) : 663 - 680
  • [24] Discovery of GDC-0032: A beta-sparing PI3K inhibitor active against PIK3CA mutant tumors.
    Olivero, Alan G.
    Heffron, Timothy P.
    Baumgardner, Matthew
    Belvin, Marcia
    Ross, Leanne Berry
    Blaquiere, Nicole
    Bradley, Erin
    Castanedo, Georgette
    Derynck, Mika
    Do, Steven
    Dotson, Jennafer
    Dudley, Danette
    Edgar, Kyle
    Folkes, Adrian
    Francis, Ross
    Gianetti, Tony
    Goldsmith, Richard
    Goldsmith, Paul
    Guan, Jane
    Harrison, Trevor
    Heald, Robert
    Hsu, Jerry
    Jackson, Phillip
    Jones, Graham
    Kim, Amy
    Kolesnikov, Aleks
    Lackner, Mark
    Lee, Leslie
    Lesnick, John
    Lewis, Cristina
    Mamounas, Michael
    McLean, Neville
    Murray, Jeremy
    Ndubaku, Chudi
    Nonomiya, Jim
    Pang, Jodie
    Pegg, Neil
    Prior, Wei Wei
    Salphati, Laurent
    Sampath, Deepack
    Sideris, Stephen
    Siu, Michael
    Staben, Steven
    Sutherlin, Daniel
    Ultsch, Mark
    Wallin, Jeff
    Wang, Lan
    Wiesmann, Christian
    Zhang, Xiaolin
    Friedman, Lori S.
    CANCER RESEARCH, 2013, 73 (08)
  • [25] Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients with PIK3CA mutant advanced solid tumors: preliminary efficacy and safety in patients with PIK3CA mutant ER -positive (ER plus ) metastatic breast cancer (MBC)
    Juric, D.
    Argiles, G.
    Burns, H. A.
    Gonzalez-Angulo, A. M.
    Saura, C.
    Quadt, C.
    Douglas, M.
    Demanse, D.
    De Buck, S.
    Baselga, J.
    CANCER RESEARCH, 2012, 72
  • [26] Gedatolisib, a pan-PI3K/mTOR inhibitor, shows superior potency and efficacy relative to other PI3K/AKT/mTOR pathway inhibitors in breast cancer models
    Rossetti, Stefano
    Broege, Aaron
    Sen, Adrish
    Khan, Salmaan
    MacNeil, Ian
    Molden, Jhomary
    Gorbatchevsky, Igor
    Sullivan, Brian F.
    Laing, Lance
    CANCER RESEARCH, 2024, 84 (09)
  • [27] Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis
    Wang, Shu
    Liu, Mingyue
    Lian, Siheng
    Liu, Naiming
    Zhang, Guibin
    Zhao, Qingchun
    Zhang, Yingshi
    Jian, Lingyan
    BIOMED RESEARCH INTERNATIONAL, 2020, 2020
  • [28] The AKT inhibitor AZD5363 is selectively active in PIK3CA mutant gastric cancer cell lines, and sensitizes a gastric cancer explant model to docetaxel
    Li, Jing
    Davies, Barry R.
    Zhou, Minhua
    Zhang, Jingchuan
    Xu, Yan
    Tang, Lili
    Wang, Huiying
    Liu, Charles
    Yin, Xiaolu
    Ji, Qunsheng
    Yu, Derek Dehua
    CANCER RESEARCH, 2012, 72
  • [29] PRECLINICAL DEVELOPMENT OF THE PI3K ALPHA SELECTIVE AND PIK3CA MUTANT SELECTIVE INHIBITOR GDC-0077 AND PREDICTION OF ITS HUMAN PHARMACOKINETICS
    Pang, Jodie
    Baumgardner, Matthew
    Braun, Marie-Gabrielle
    Cheong, Jonathan
    Edgar, Kyle
    Friedman, Lori
    Hanan, Emily
    Jaochico, Allan
    Ma, Shuguang
    Plise, Emile
    Schmidt, Stephen
    Liu, Ning
    Song, Kyung
    Staben, Steve
    Salphati, Laurent
    DRUG METABOLISM AND PHARMACOKINETICS, 2019, 34 (01) : S37 - S37
  • [30] Gedatolisib, a well-tolerated pan-PI3K/mTOR inhibitor, exhibits potent therapeutic effects on endometrial cancer models regardless of their PI3K pathway mutational status
    Rossetti, Stefano
    Broege, Aaron
    MacNeil, Ian
    Rich, Ben
    Molden, Jhomary
    Sullivan, Brian
    Laing, Lance
    CANCER RESEARCH, 2023, 83 (07)
12345